[Beijing, China | May 10-13, 2026] Members of our research group attended The 9th China-Europe Symposium on Biomaterials in Regenerative Medicine (CESB 2026). Prof. Cheng delivered a Keynote Lecture titled “Development of Covalent Targeting Therapeutics Based on In Vivo Click Chemistry”.
[Hangzhou, May 6th, 2026] Hangzhou Surio Therapeutics Co., Ltd. (“Surio”), a biopharmaceutical company dedicated to developing first-in-class therapies to address unmet medical needs in oncology, today announced the successful completion of the Phase Ia clinical study for its investigational drug, SURIO-001. The trial, conducted by its subsidiary Avisure, evaluated the drug in healthy subjects. The study results demonstrated that the ST114 molecule in the SURIO-001 combination exhibited a favorable safety and tolerability profile in healthy subjects with no grade 2 or higher adverse event. Predefined pharmacokinetic objectives were also achieved. These data provide a robust foundation for subsequent clinical investigation in cancer patients. Based on the positive safety and tolerability results from the Phase Ia study, the company will initiate the Phase Ib clinical trial of the drug very soon.
Members of our research group attended The 35th CCS Congress, Zhen Yuan delivered a Flash Report and shared her work about Synthesis and Applications of Supra-Natural β-Sheet-Based Polypeptides.
Recently, Cao Tingting, a Ph.D. student in Professor Cheng Jianjun’s lab at the School of Engineering, Westlake University, was selected for the “2026 Excellence in Graduate Polymer Research Symposium” and invited to present a poster. She is also the only Ph.D. student from a Chinese university among the 36 selected participants worldwide this year.
[March 26th, 2026] The inaugural AbbVie China Innovation Award results were officially announced at the 2026 AbbVie China Partnering Day. Surio Therapeutics successfully won the only award in the therapeutics area for its first-in-class ATTACK technology. The award was announced by Dr. Cathy Xiao, Development Head, AbbVie China, and Dr. Christian R. Schubert, Vice President and Head of AbbVie Ventures. Dr. Kaimin Cai, Co-founder and Chief Technology Officer of Surio Therapeutics, received the award on behalf of the company. This recognition signifies professional appreciation from a globally prestigious biopharma regarding Surio Therapeutics' leading technology.
DNA-based neural networks are emerging as a biocompatible and energy-saving computing paradigm, but they have long been constrained by the lack of hardware reusability. In this work, we establish an unprecedented noncomplementary DNA-based neural network that relies exclusively on reversible strand-displacement reactions, providing an inherently reusable computing framework capable of multibit ...
Hangzhou, China, September, 9th, 2025, Surio Therapeutics Co. Ltd announces IND clearance for first-in-class targeted cancer therapeutics SURIO-001 from Center for Drug Evaluation (CDE), NMPA, China. Surio will initiate Phase I clinical trial in China soon
PhD candidate Tingting Cao has published a research article titled " Controlled synthesis of telechelic polypeptides via polymerization of N-carboxyanhydrides mediated by phosphate kinetic modulators" in ACS Macro Letters.
Members of our research group attended The 13th Chinese National Conference on chemical biology, Wenjing XUAN delivered an oral report and shared her work.
Chenlin participated in Virtual Graduate Students Symposium in Asia-Pacific Region on Polymer Chemistryand delivered a speech titled "Cooperative Polymerization on Two-Phase Interface for Synthesis of Polypeptides by Unpurified N-carboxyanhydrides"
Dr. Menghua Gao's work elucidated the importance of PEG-lipid structure optimization and modification in balancing LNP circulation and clearance during the rational design of the mRNA-LNP system.
The group meeting brought together teachers and students from Tao Lin's laboratory, Kaicheng Yu's Laboratory, Jianjun Cheng's Laboratory and Yue Zhang's laboratory to conduct in-depth discussions on cutting-edge academic topics.
Address：No. 600 Dunyu Road, Sandun Town, Xihu District 310030 Hangzhou, Zhejiang PR China
Email：chengjianjun@westlake.edu.cn (research affairs)
